Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2

References

• Askari AA, Thomson S, Edin ML, Lih FB, Zeldin DC, Bishop-Bailey D. 2014. Basal and inducible anti-inflammatory epoxygenase activity in endothelial cells. Biochem Biophys Res Commun. 446(2):633–637.
   PubMed Web of Science ®Google Scholar
• Atone J, Wagner K, Hashimoto K, Hammock BD. 2020. Cytochrome P450 derived epoxidized fatty acids as a therapeutic tool against neuroinflammatory diseases. Prostaglandins Other Lipid Mediat. 147:106385.
   PubMed Web of Science ®Google Scholar
• Bao S, Wen J, Zheng X, Zhou Q, Qu G, Chen M, Hu G. 2018. Evaluation of the inhibition effects of apatinib on human and rat cytochrome P450. Toxicol Lett. 297:1–7.
   PubMed Web of Science ®Google Scholar
• Bièche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, de Waziers I. 2007. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics. 17(9):731–742.
   PubMed Web of Science ®Google Scholar
• Chen C, Wei X, Rao X, Wu J, Yang S, Chen F, Ma D, Zhou J, Dackor RT, Zeldin DC, et al. 2011. Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth. J Pharmacol Exp Ther. 336(2):344–355.
   PubMed Web of Science ®Google Scholar
• Ding J, Chen X, Dai X, Zhong D. 2012. Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 895–896:108–115.
   PubMed Web of Science ®Google Scholar
• Ding J, Chen X, Gao Z, Dai X, Li L, Xie C, Jiang H, Zhang L, Zhong D. 2013. Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos. 41(6):1195–1210.
   PubMed Web of Science ®Google Scholar
• Filppula AM, Mustonen TM, Backman JT. 2018. In vitro screening of six protein kinase inhibitors for time-dependent inhibition of CYP2C8 and CYP3A4: possible implications with regard to drug-drug interactions. Basic Clin Pharmacol Toxicol. 123(6):739–748.
   PubMed Web of Science ®Google Scholar
• Gao S, Li X, Shi W, Huo L, Liu H. 2022. Efficacy of the low dose apatinib plus chemotherapy on advanced gastric carcinoma. J Oncol. 2022:3009494.
   PubMedGoogle Scholar
• Gui L, Xu Q, Huang J, Wu G, Tang H, Hui L, Hua P, Zhang L, Zhu Y. 2020. CYP2J2 promotes the development of hepatocellular carcinoma by increasing the EETs production to improve HIF-1α stability. Am J Transl Res. 12(12):7923–7937.
   PubMed Web of Science ®Google Scholar
• Ikemura N, Yamaori S, Kobayashi C, Kamijo S, Murayama N, Yamazaki H, Ohmori S. 2019. Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chem Biol Interact. 306:1–9.
   PubMed Web of Science ®Google Scholar
• Jeon YJ, Kim JS, Hwang GH, Wu Z, Han HJ, Park SH, Chang W, Kim LK, Lee Y-M, Liu K-H, Lee MY. 2015. Inhibition of cytochrome P450 2J2 by tanshinone IIA induces apoptotic cell death in hepatocellular carcinoma HepG2 cells. Eur J Pharmacol. 764:480–488.
   PubMed Web of Science ®Google Scholar
• Jiang J-G, Chen C-L, Card JW, Yang S, Chen J-X, Fu X-N, Ning Y-G, Xiao X, Zeldin DC, Wang DW. 2005. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 65(11):4707–4715.
   PubMed Web of Science ®Google Scholar
• Jiang J-G, Fu X-N, Chen C-L, Wang D-W. 2009. Expression of cytochrome P450 arachidonic acid epoxygenase 2J2 in human tumor tissues and cell lines. Ai Zheng Chin J Cancer. 28(2):93–96.
   PubMedGoogle Scholar
• Jiang J-G, Ning Y-G, Chen C, Ma D, Liu Z-J, Yang S, Zhou J, Xiao X, Zhang XA, Edin ML, et al. 2007. Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res. 67(14):6665–6674.
   PubMed Web of Science ®Google Scholar
• Karkhanis A, Hong Y, Chan ECY. 2017. Inhibition and inactivation of human CYP2J2: implications in cardiac pathophysiology and opportunities in cancer therapy. Biochem Pharmacol. 135:12–21.
   PubMed Web of Science ®Google Scholar
• Karkhanis A, Lam HY, Venkatesan G, Koh SK, Chai CLL, Zhou L, Hong Y, Kojodjojo P, Chan ECY. 2016. Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites. Biochem Pharmacol. 107:67–80.
   PubMed Web of Science ®Google Scholar
• Kojima A, Sogabe A, Nadai M, Katoh M. 2021. Species differences in oxidative metabolism of regorafenib. Xenobiotica. 51(12):1400–1407.
   PubMed Web of Science ®Google Scholar
• Lai J, Chen C. 2021. The role of epoxyeicosatrienoic acids in cardiac remodeling. Front Physiol. 12:642470.
   PubMed Web of Science ®Google Scholar
• Lee B, Wu Z, Sung SH, Lee T, Song K-S, Lee MY, Liu K-H. 2014. Potential of decursin to inhibit the human cytochrome P450 2J2 isoform. Food Chem Toxicol. 70:94–99.
   PubMed Web of Science ®Google Scholar
• Lee CA, Jones JP, Katayama J, Kaspera R, Jiang Y, Freiwald S, Smith E, Walker GS, Totah RA. 2012. Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos. 40(5):943–951.
   PubMed Web of Science ®Google Scholar
• Lim HM, Lee J, Yu SH, Nam MJ, Cha HS, Park K, Yang Y-H, Jang KY, Park S-H. 2022. Acetylshikonin, a novel CYP2J2 inhibitor, induces apoptosis in RCC cells via FOXO3 activation and ROS elevation. Oxid Med Cell Longev. 2022:9139338.
   PubMed Web of Science ®Google Scholar
• Lu J, Liu D, Zhou X, Chen A, Jiang Z, Ye X, Liu M, Wang X. 2018. Plant natural product plumbagin presents potent inhibitory effect on human cytochrome P450 2J2 enzyme. Phytomedicine. 39:137–145.
   PubMed Web of Science ®Google Scholar
• Narjoz C, Favre A, McMullen J, Kiehl P, Montemurro M, Figg WD, Beaune P, de Waziers I, Rochat B. 2014. Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance. PLoS One. 9(5):e95532.
   PubMed Web of Science ®Google Scholar
• Park S-H, Phuc NM, Lee J, Wu Z, Kim J, Kim H, Kim N. d, Lee T, Song K-S, Liu K-H. 2017. Identification of acetylshikonin as the novel CYP2J2 inhibitor with anti-cancer activity in HepG2 cells. Phytomedicine. 24:134–140.
   PubMed Web of Science ®Google Scholar
• Sherman SI, Wirth LJ, Droz J-P, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun Y-N, Juan T, et al.; Motesanib Thyroid Cancer Study Group. 2008. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 359(1):31–42.
   PubMed Web of Science ®Google Scholar
• Sisignano M, Angioni C, Park C-K, Meyer Dos Santos S, Jordan H, Kuzikov M, Liu D, Zinn S, Hohman SW, Schreiber Y, et al. 2016. Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain. Proc Natl Acad Sci U S A. 113(44):12544–12549.
   PubMed Web of Science ®Google Scholar
• Sun T, Chen L, Kan X, Ren Y, Cao Y, Zhang W, Lu H, Zheng C. 2022. A comparative analysis of efficacy of apatinib combined with transarterial chemoembolization and transarterial chemoembolization alone in the treatment of hepatocellular carcinoma with portal vein tumor thrombus. J Oncol. 2022:1255133.
   PubMed Web of Science ®Google Scholar
• Tang LWT, Wu G, Chan ECY. 2022. Identification of infigratinib as a potent reversible inhibitor and mechanism-based inactivator of CYP2J2: nascent evidence for a potential in vivo metabolic drug-drug interaction with rivaroxaban. J Pharmacol Exp Ther. 382(2):123–134.
   PubMed Web of Science ®Google Scholar
• Tian Z, Niu X, Yao W. 2021. Efficacy and response biomarkers of apatinib in the treatment of malignancies in China. Front Oncol. 11:749083.
   PubMed Web of Science ®Google Scholar
• Wang C, Ying L, Jin M, Zhang F, Shi D, Dai Y, Zhou Z. 2021. An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib. Cancer Chemother Pharmacol. 87(1):43–52.
   PubMed Web of Science ®Google Scholar
• Wang X, Owzar K, Gupta P, Larson RA, Mulkey F, Miller AA, Lewis LD, Hurd D, Vij R, Ratain MJ, et al.; Alliance for Clinical Trials in Oncology. 2014. Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol. 78(5):1005–1013.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yong Chan EC. 2022. Inhibition of cytochrome P450 2J2-mediated metabolism of rivaroxaban and arachidonic acid by ibrutinib and osimertinib. Drug Metab Dispos. 50(10):1332–1341.
   PubMed Web of Science ®Google Scholar
• Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. 1996. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem. 271(7):3460–3468.
   PubMed Web of Science ®Google Scholar
• Xu M, Ju W, Hao H, Wang G, Li P. 2013. Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance. Drug Metab Rev. 45(3):311–352.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Okayama A, Imai N, Guengerich FP, Shimizu M. 2006. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica. 36(12):1201–1209.
   PubMed Web of Science ®Google Scholar
• Zhu Y-T, Teng Z, Zhang Y-F, Li W, Guo L-X, Liu Y-P, Qu X-J, Wang Q-R, Mao S-Y, Chen X-Y, et al. 2020. Effects of apatinib on the pharmacokinetics of nifedipine and warfarin in patients with advanced solid tumors. Drug Des Devel Ther. 14:1963–1970.
   PubMed Web of Science ®Google Scholar
• Zou X, Mo Z. 2021. CYP2J2 is a diagnostic and prognostic biomarker associated with immune infiltration in kidney renal clear cell carcinoma. Biomed Res Int. 2021:3771866.
   PubMed Web of Science ®Google Scholar